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Abstract
Background: WS070117 is a novel small molecule compound that significantly improves lipid metabolism
disorders in high-fat-diet (HFD) induced hyperlipidemia in hamsters.
Methods and Results: We evaluated liver/body weight ratio, liver histology, serum and hepatic lipid content in
HFD-fed hamsters treated with WS070117 for 8 weeks. Comparing with HFD fed hamsters, WS070117 (2 mg/kg per
day and above) reduced serum triglyceride (TAG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C)
and hepatic cholesterol and triglyceride contents. Oil Red O staining of liver tissue also showed that WS070117
improved lipid accumulation. We then carried out an experiment in the oleic acid (OLA)-induced steatosis model
in HepG2 cell to investigate the lipid-lowering effect of WS070117. Oleic acid (0.25 mM) markedly induced lipid
accumulation in HepG2 cells, but WS070117 (10 μM) inhibited cellular lipid accumulation. In OLA-treated HepG2
cells, WS070117 (above 1 μM) treatment reduced lipid contents which synthesized from [1-
14C] labeled acetic acid.
Because WS070117 is an analog of adenosine, we evaluated the effect of WS070117 on AMP-activated protein
kinase (AMPK) signaling. The results showed that the activation of AMPK in OLA-induced steatosis in HepG2 cells
was up-regulated by treatment with 0.1, 1 and 10 μM WS070117. The hepatic cellular AMPK phosphorylation is also
up regulated by WS070117 (6 and 18 mg/kg) treatment in HFD fed hamsters.
Conclusion: These new findings identify WS070117 as a novel molecule that regulates lipid metabolism in the
hyperlipidemia hamster model. In vitro and in vivo studies suggested that WS070117 may regulate lipid
metabolism through stimulating the activation of AMPK and its downstream pathways.
Background
Metabolism syndromes are often linked to the macronu-
trient content of the diet and there is evidence that
excessive consumption of macronutrients such as carbo-
hydrates, fats, and even protein may eventually lead to
the development of metabolic syndromes [1]. Diets high
in fats and cholesterol have been demonstrated to
induce weight gain, insulin resistance and hyperlipide-
mia in humans and animal models [2]. Control of
serum lipids is important to prevent cardiovascular
events. For many patients, however, achievement of
tight serum lipid control by diet is difficult, requiring
therapy with drugs [3]. Statins are one of the most
widely used classes of drugs in clinical anti-
hyperlipidemia therapy. However, availability of drugs
that alleviate dyslipidemia syndromes is somewhat lim-
ited, warranting the discovery and characterization of
novel molecules targeting various pathways involved in
the pathogenesis of hyperlipidemia.
Activation of AMP-activated protein kinase (AMPK), a
heterotrimeric energy-sensing protein, acts to restore
cellular energy balance by promoting ATP-generating
pathways such as fatty acid oxidation while simulta-
neously inhibiting ATP-utilizing pathways such as fatty
acid synthesis [4]. Historically, the primary function of
AMPK was to generate ATP when cellular levels are
low. The AMPK system plays a major role in the regula-
tion of hepatic glucose and lipid metabolism through its
acute effects on energy metabolism and long-term
effects on gene expression patterns in the liver [5]. Simi-
larly, pharmacological activation of AMPK by metformin
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reverses fatty liver in obese humans and mice [6,7].
Therefore, it is clearly an attractive therapeutic target in
cardio-metabolic diseases.
During our screening for AMPK activators, we seren-
dipitously identified WS070117 as a lead compound
with potent lipid-regulating properties. The objective of
this study was to evaluate the impact of WS070117 on
an animal and cellular model of hyperlipidemia. Studies
in the hamster hyperlipidemia model revealed that
WS070117 markedly improved lipid abnormalities asso-
ciated with conditions characteristic of the high fat diet
(HFD)-induced lipid metabolism disorder. Investigations
into cellular signaling mechanisms suggested that
WS070117 may produce the lipid-regulating effects by
the phosphorylation of the AMPK signaling pathway.
Methods
Synthesis of WS070117
The synthesis of O
2’,O
3’,O
5’-tri-acetyl-N6-(3-hydroxylani-
line)adenosine, named as WS070117 (Figure 1A), began
with acetylation of inosine using commercially available
acetic anhydride, chlorination with SOCl2, and substitution
with 3-aminophenol. Briefly, acetic anhydride was added
to a suspension of inosine in dry pyridine at 0°C and stir-
red at room temperature for 6 h to yield the pure product
O
2’,O
3’,O
5’-tri-acetylinosine (Compound 1). Compound 1
was then dissolved in dry CH2Cl2:DMF (50:1) and a solu-
tion of SOCl2 in CH2Cl2 was added in a drop-wise manner.
After dilution with CH2Cl2, the organic layer of the reac-
tion mixture was washed with saturated NaHCO3 solution
and brine and dried with anhydrous sodium sulfate. To a
solution of O
2’,O
3’,O
5’-triacetyl-6-chloroadenosine in abso-
lute ethanol was added 3-aminophenol and dry triethyla-
mine. The mixture was then refluxed for 8 h at 60°C. The
solution was concentrated in vacuum and the residue was
chromatographed (ethyl acetate:petroleum ether, 2:1) to
give WS070117 as a white solid.
Animal
Golden hamsters (12-month-old) were purchased from
Vital River Laboratory Animal Technology Co. Ltd. (Beij-
ing, China). All animal treatment procedures described
in this study were approved by the Animal Care and Use
Committee at the Institute of Materia Medica, Chinese
Academy of Medical Sciences and Peking Union Medical
College (Beijing, China). Animals were housed under
well-controlled conditions of temperature (22 ± 2°C),
humidity (55 ± 5%) and a 12 h light-dark cycle with
access to food and water ad libitum.
Experiment design and drug administration
Except the control hamsters (n = 5), other hamsters (n
= 40) were fed high fat diet (HFD) accustomedly for 2
weeks, blood was collected from orbit vein for assaying
the content of serum total cholesterol and triglyceride
for grouping. Then, The HFD fed hamsters were divided
into the following groups with eight animals per group
respectively, accounted into their body weight and the
levels of serum total cholesterol and triglyceride, HFD
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Figure 1 A novel structure compound, WS070117, activated
AMPK in HepG2 cells. A: Structure of WS070117; B: Effect of
WS070117 on AMPK activity in HepG2 cells detected by AMPK
activity assays with SAMS peptide and [g-32P]ATP used as
substrates. HepG2 cells were treated with WS070117 (10 μM) for 1h,
6h and 12h. C: Effect of 12h treatment of WS070117 (1,10,100 μM)
or AICAR (1 mM) on AMPK activity of HepG2 cells. AMPK activities
are expressed relative to activity detected in HepG2 cells lysate.
Each point is the mean (± SEM) of 3 separate experiments. **P <
0.01, *P < 0.05 as compared with control.
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group, HFD+WS070117 low dose group (2 mg/kg),
HFD+WS070117 middle dose group (6 mg/kg) and
HFD+WS070117 high dose group (18 mg/kg). The ani-
mals in normal control group were fed ordinary diet,
and the other groups were still fed HFD ad libitum for
8 weeks with the indicated drugs oral administration.
WS070117 was dissolved in distilled water prior to
administration. All drugs were given once daily by oral
gavage for 8 weeks. The animals in the normal control
and in the HFD model control group received the same
volum of distilled water as that of the drug-treated
groups.
Cell culture and treatment
The hepatic cell line HepG2 was purchased from the
Cell Resource Center(IBMS, CAMS/PUMC, Beijing
China) was grown in Dulbecco’s modified Eagle’sm e d -
ium (DMEM, GIBCO, NY, USA) supplemented with
10% fetal bovine serum (FBS, MDgenics, St. Louis, MO,
USA) and 1% penicillin-streptomycin under a humidi-
fied atmosphere of 5% CO2 in air. After growth to 70%
to 80% confluence, cells were rendered quiescent by
incubating with serum-free medium for 12 h before
fatty acid treatment. For OLA-induced lipid deposition,
the medium for cells at 75% confluence was exchanged
for new medium with or without 0.25 mmol/L OLA
( S i g m a ,S t .L o u i s ,M O ,U S A )[ 8 ] .M e a n w h i l e ,d i f f e r e n t
concentration of WS070117 was added into medium
and treated with OLA for 12h.
Serum isolation and cholesterol determination
Blood samples were collected from the retro-orbital
plexus 1 h after drug treatments. Serum was isolated at
room temperature. Standard enzymatic methods were
used to determine TC, TAG, LDL-c and high density
lipoprotein cholesterol (HDL-C) levels with commer-
cially available kits purchased from Bio Sino Bio-tech-
nology and Science Inc. (Beijing, China). Each sample
was assayed in duplicate.
Measurement of hepatic TAG and TC contents in hamster
livers
100 mg of hamster liver tissue was taken for lipid
extraction. Briefly, the frozen tissue was thawed and
homogenized with a motor driven homogenizer in 2 ml
chloroform/methanol (2:1). After homogenization, lipids
were further extracted by rocking samples for 1 h at
room temperature, followed by centrifugation at 5,000
r p mf o r1 0m i n .T h el i q u i dp h a s ew a sw a s h e dw i t h0 . 2
volume of 0.9% saline. The mixture was centrifuged
again at 2,000 rpm for 5 min to separate the two phases.
The lower phase containing lipids was evaporated and
lipids were dissolved in 0.5 ml isopropanol containing
10% Triton X-100 for TAG and TC measurements.
Oil red O stain
For histological examination, pieces of liver tissues were
fixed in 4% paraformaldehyde and dehydrated in 30%
sucrose solution at room temperature. Tissues were
then immersed in Optimal Cutting Temperature (OCT)
solution on dry ice for Oil Red O staining. Three ham-
ster livers were randomly picked from each group and
three different tissue sections from each liver were pro-
cessed and stained using routine laboratory procedures.
For fat accumulation examination in HepG2 cells, cul-
ture dishes were washed with cold phosphate-buffered
saline and fixed in 4% paraformaldehyde. After 2
changes of 60% isopropanol, Oil-Red-O was added with
agitation for 10 minutes, followed by washing in 50%
isopropanol. For each dish, 3 images were photo-
graphed, and a representative image is shown.
AMP-activated protein kinase (AMPK) activity assay
AMPK activity assays were performed on lysates of
HepG2 cells cultured in 6-well plates with 10% FBS/
DMEM supplemented with 1,6,12 hours time course
(10 μM) and 1,10,100 μM dosage (12 hours) of
WS070117 by measurement of [g-
32P]ATP (Perkin-
Elmer, Boston, MA, USA) radioactivity phosphorylated
by a synthetic peptide substrate, SAMS [9]. AMPK
activity was expressed as nmol of phosphate incorpo-
rated into the peptide substrate per min per mg of
lysate (nmol/min/mg).
Lipid synthesis assay
OLA HepG2 cells was co-incubated with 0.1,1 and 10
μM WS070117 for 12h. Incorporation of [1
-14C] acetic
acid (Perkin-Elmer, Boston, MA, USA) into lipid was
performed as described previously [10]. After replace-
ment with 1 ml of fresh medium, the cellular lipid was
labeled by incubating for 2.5 h with [1
-14C] acetic acid
(0.2 μCi/ml). Lipid was extracted with n-hexane:2-pro-
panol (3:2, v/v) and dried under a nitrogen stream. Ali-
quots of lipid samples were loaded onto thin-layer
chromatography plates and chromatographed in a sol-
vent mixture containing hexane-diethylether-acetic acid
(85:30:1, v/v/v). Bands corresponding to triglyceride and
cholesteryl ester were scraped off, immersed in non-
aqueous scintillation fluid, and counted for radioactivity.
Western blot analysis
The expression and phosphorylation of each protein
were analyzed by Western blot analysis. Briefly, protein
lysates were subjected to 10% SDS-polyacrylamide gel
electrophoresis. Proteins were transferred to a
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blocked for 1 h at room temperature with 5% non-fat
dry milk in Tris-buffered saline (TBS) containing 0.1%
Tween 20. Immunostaining to detect each protein was
achieved after over-night incubation (4°C) with a 1:1000
dilution of anti-phospho (thr-172) AMPK (1:2000),
AMPK (1:2000) and anti-beta-actin (1:5000). Proteins
were visualized after subsequent incubation with a
1:5000 dilution of anti-mouse or rabbit IgG conjugated
to horseradish peroxidase and use of a Super Signal
Chemical luminescence detection procedure. All antibo-
dies used in this study were from Cell Signaling Tech-
nology Inc. (Beverly, MA, USA). Protein concentrations
were determined using a bicinchoninic acid assay
(Applygen Inc., Beijing China). Three independent
experiments were performed for each condition and the
intensity of immune-reactive bands was analyzed with a
Bio-Rad calibrated densitometer.
Statistical analyses
One-way ANOVA was used to determine significant dif-
ferences among groups, after which the modified Stu-
dent’s t-test with the Bonferroni correction was used for
comparison between individual groups. P < 0.05 was
considered statistically significant.
Results
WS070117 increased AMPK activity
AMPK has been proposed to act as a fuel gauge in
mammalian cells and to play a crucial role in regulating
fat metabolism in the liver. The major pathways that
regulate intracellular lipid metabolism are evidently pre-
sent in HepG2 cells. The change of AMPK activity in
HepG2 cells is strongly associated with intracellular
lipid metabolism. Because WS070117 is an adenosine
analogue, we studied the possibility that WS070117
could activate AMPK. Incubation of HepG2 cells with 1
~1 0 0μM WS070117 for 12h significantly activated
AMPK, as measured in cell lysates. WS070117 also acti-
vated AMPK in a time dependently manner within 12
hours treatment. AICAR, one of the potent AMPK acti-
vators, also increased AMPK activity (Figure 1B, C).
In vivo reductions of plasma and hepatic lipid contents
by WS070117
HFD with obese hamsters fed a diet containing 20% fat
was used for producing the lipid metabolism dyslipide-
mia model. After 8 weeks, hamster body weights
increased about 20% with no difference among the HFD
treated groups. The liver/body weight ratio was mark-
edly increased at the end of the experiment. The
increases in the groups treated with WS070117 were
significantly decreased the liver hypertrophy as com-
pared with the HFD group (Table 1). WS070117 (2, 6 or
18 mg/kg/day) treatment resulted in significant
decreases in serum TC, TAG and LDL-c as well as
hepatic TAG and TC (Figure 2B).
Oil Red O staining of livers showed that the hepato-
cytes of animals in the HFD group were compressed
and separated by bulks of fat, demonstrating the abnor-
mally high levels of fat accumulation in liver (Figure
2A). 8 weeks treatment with 18 mg/kg WS070117 sub-
stantially repressed these changes in HFD hamsters.
Therefore, WS070117 helped to keep normal fat accu-
mulation and deposition under HFD feeding conditions.
WS070117 decreases lipid accumulation and de novo
fatty acid synthesis in vitro
Hepatic steatosis in humans is associated with accumu-
lation of excess OLA and the end-product of de novo
fatty acid synthesis [4]. AMPK-mediated phosphoryla-
tion of protein targets involved in cholesterol and fatty
acids synthesis, however, lead to inhibition of cholesterol
and TAG synthesis. In present study, Oil Red O staining
showed that 10 μM WS070117 decreased the lipid accu-
mulation in HepG2 cells induced by 250 μM OLA (Fig-
ure 3A). We then evaluated the impact of WS070117 on
TAG and cholesterol synthesis by incubating HepG2
cells for 2 h with [
14C]acetate in the presence of increas-
ing concentrations of WS070117 (Figure 3B). Both
Table 1 Hamsters were fed with normal chow or high fat diet (HFD) for 10 weeks
Control(n = 5) HFD(n = 8) HDF+WS070117 HFD+Simvastatin 2 mg/kg(n = 8)
2 mg/kg(n = 8) 6 mg/kg(n = 8) 18 mg/kg(n = 8)
TAG (mmol/L) 2.05 ± 0.52 10.98 ± 5.84
## 6.52 ± 2.75 5.91 ± 1.98* 4.51 ± 1.88** 6.18 ± 1.28*
TC (mmol/L) 3.95 ± 0.54 9.22 ± 3.87
## 7.33 ± 1.84 6.81 ± 1.49 6.11 ± 0.65* 7.73 ± 1.31*
HDL (mmol/L) 1.48 ± 0.25 3.18 ± 1.46
# 2.56 ± 0.89 2.45 ± 0.90 2.14 ± 0.26 2.51 ± 0.60
LDL (mmol/L) 2.40 ± 0.36 5.30 ± 2.01
## 4.43 ± 0.58 3.97 ± 0.75* 3.16 ± 0.43** 2.51 ± 0.45*
Body weight 136 ± 16.5 168.8 ± 14.7
## 166.5 ± 9.3 165.2 ± 15.7 164.5 ± 13.6 166.7 ± 12.6
Liver/Body weight 0.039 ± 0.0054 0.049 ± 0.0046
## 0.044 ± 0.0056* 0.044 ± 0.0034* 0.045 ± 0.0023* 0.045 ± 0.0018*
Serum was separated after 8 weeks of WS070117 and Simvastatin treatment at the indicated doses from hamsters fed a high fat diet (HFD). The actual valueso f
mean ± SD from 8 animals (control group, n = 5) are presented.
##P < 0.01,
#P < 0.05, as compared to vehicle control; ** P < 0.01, *P< 0.05 as compared to HFD
model.
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inhibited by WS070117 (0.1 ~ 10 μM).
Effect of WS070117 on phosphorylation and activation of
AMPK in HepG2 cells and liver tissue
AMPK activation is thought to be a key proximal event in
the cellular energy balance response, and AMPK
phosphorylation levels are currently accepted as a marker
of AMPK activity. Therefore, we determined the phos-
phorylation of AMPK in OLA overload HepG2 cells.
After 12h treatment of WS070117, AMPK phosphoryla-
tion is activated at 0.1 10 and 1 μM. In HFD-fed hamster
livers, AMPK phosphorylation was also increased by
treatment with 6 or 18 mg/kg WS070117 (Figure 4).
A 
 
B 
HFD
HFD+WS070117(18mg/kg)
Control
HFD+ Simvastatin (2mg/kg)
Figure 2 Effects of WS070117 on hepatic lipids accumulation in HFD fed hamsters. A: Representative frozen tissue sections of liver taken
from hamsters fed chow diet, HDF diet, HFD+ simvastatin (2 mg/kg) and HFD+WS070117 (18 mg/kg) were stained with Oil Red-O to
demonstrate the reduction in lipid droplets. B: Hepatic TC and TAG were measured in liver samples of control (n = 5), HFD, 8-weeks WS070117
(2, 6, 18 mg/kg) or simvastatin (positive control; 2 mg/kg) treated HFD fed hamsters (n = 8). **P < 0.01, *P < 0.05 as compared with HFD model.
##P < 0.01 as compared with control.
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The key finding of our present studies is that a novel syn-
thetic small molecule, WS070117, alleviates dietary (i.e.,
HFD) induced lipid metabolism disorder in hamsters.
Male Golden Syrian hamster, a widely used model in
studying atherosclerosis and cholesterol metabolism in
response to dietary fat manipulations, has many similar
profiles in lipid metabolism compared to humans [11].
HFD that contains 20% saturated fat induces increases in
hamster serum TAG, TC, LDL-C within 1 week; the
higher levels reach a stable state after 4 weeks of treat-
ment, as previously described [12,13]. After treatment for
8 weeks on a HFD (20% fat, 2% cholesterol), hamsters
exhibit an obvious hyperlipidemia syndrome. WS070117
treatment markedly improved the impaired serum lipid
content, suggesting that WS070117 regulates lipid meta-
bolism to alleviate the hyperlipidemia. The chronic HFD
causes caloric surplus. When the lipid supply exceeds
energy consumption, a gradual accumulation of ectopic
fatty acids begins. Excessive ectopic triglyceride deposi-
tion in liver can impair perfectly normal hepatocytes and
then induce hepatic steatosis [14]. In the present study,
the Oil Red O staining of liver sections showed signifi-
cant lipid accumulation in HFD treatment groups. Long-
term feeding (8 weeks) of the HFD induced severe hepa-
tic steatosis. WS070117 treatment significantly sup-
pressed the increase of liver fat accumulation that was
evoked by the HFD. WS070117 treatment was also asso-
ciated with a reduction in the gain in body mass in the
HFD-fed hamsters. Serum glucose was increased after
HFD treatment, but WS070117 showed no effect on glu-
cose metabolism (data not shown).
The nucleus of the parent molecule from which
WS070117 is derived is an analogue of adenosine. Pre-
viously, several groups demonstrated that adenosine is
an effective activator of AMPK [15,16]. In the present in
vitro studies, we found that WS070117 activated AMPK
in HepG2 cells. AMPK is considered a master switch in
A 
B 
OLA(250ȝ0) OLA+WS070117 (10ȝ0) 
Figure 3 Effects of WS070117 on steatosis and de novo lipids synthesis in OLA-HepG2 cells. A: Oil Red O stain of 0.25 mM OLA-induced
cellular lipid accumulation in WS070117 treated HepG2 cells. 12h treatment of WS070117 (10 μM) reduced the lipid droplets amount in HepG2
cells. B: TAG and TC synthesis was measured by the lipid accumulated from [1-
14C] acetic acid, and was measured in control and WS070117 (0.1,
1, 10 μM) 12-h-treated OLA-HepG2 cells. **P < 0.01, *P < 0.05 as compared with OLA or HFD models.
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enzyme that works as a fuel gauge, being activated in
conditions of high-energy phosphate depletion. In the
liver, activation of AMPK results in decreased produc-
tion of plasma cholesterol, triglyceride and enhanced
fatty acid oxidation [17,18]. These facts suggested that
WS070117 suppresses hepatic lipid accumulation possi-
bly through activation of hepatocyte AMPK. HMG-CoA
and acetyl CoA carboxylase (ACC), key enzymes in cho-
lesterol and fatty acid synthesis, respectively, were the
first enzymes shown to be phosphorylated and inacti-
vated by AMPK [17,19]. In the cholesterol synthesis
pathway, AMPK blocks the conversion of HMG-CoA to
mevalonate. ACC is an important rate-controlling
enzyme for the synthesis of malonyl-CoA, which is a
critical precursor for biosynthesis of fatty acids. AMPK
induced ACC phosphorylation is impaired in hepato-
cytes deleted of catalytic subunit, contributing to
increased intracellular malonyl-CoA levels and triglycer-
ide accumulation in the liver [20]. These findings
demonstrated that WS070117 is an effective activator of
AMPK with potential capability of inhibition of de novo
hepatic lipogenesis.
To reinforce the lipid metabolism relevance of these
cellular observations, we investigated the impact of
WS070117 on OLA-treated HepG2 cells. Treatment of
HepG2 cells with OLA induces morphological changes
similar to those in steatotic hepatocytes [21,22]. Hepatic
steatosis in humans is associated with accumulation of
excess oleic acid, a monosaturated omega-9 fatty acid
and the end-product of de novo fatty acid synthesis [23].
After WS070117 treatment, phospho-AMPK levels
increased inside the cells, as demonstrated by Western
blot experiments. As mentioned above, AMPK has been
proposed to play a key role in the regulation of lipid
metabolism. WS070117 significantly inhibited de novo
hepatic cholesterol and triglyceride synthesis from [
14C]
acetate in OLA-treated HepG2 cells. When compared
with the well-known AMPK activator AICAR, WS070117
induced a similar profile of effects on lipid synthesis, with
inhibition of cholesterol and TAG synthesis. We con-
clude that activation of AMPK induced by WS070117
could be responsible for its lipid lowering profile.
Inhibition of hepatic lipogenesis is strongly associated
with the anti-hepatic steatosis effect of WS070117.
Endogenous OLA mediates the induction of de novo
 
 
 
Figure 4 WS070117 treatment increases AMP-activated protein kinase (AMPK) phosphorylation in OLA-induced HepG2 cells and HFD
fed hamster livers. Data depict at least 3 experiments.* * P < 0.01 as compared with OLA and HFD groups.
##P < 0.01 as compared with
control groups.
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saturated fat [24]. Reduced rates of de novo lipogenesis
cause reduction of adipose stores. In the present study,
we found that WS070117 treatment significantly
decreased neutral lipid content accumulation in OLA-
treated HepG2 cells. This result suggests that the inhibi-
tion of lipid synthesis on OLA-treated HepG2 cells by
WS070117 treatment blocks the progress of hepatocyte
steatosis. WS070117 also exhibited a similar stimulatory
effect on AMPK phosphorylation of liver tissue in HFD-
fed hamsters. Hence, the mechanism of action of
WS070117 on diminution of hepatic fat storage in vivo
appears to be similar to that which we demonstrated in
the in vitro studies. We speculate that this decrease in
hepatic lipid content mediated by AMPK could lead to
the improved liver function in HFD-fed hamsters.
Conclusion
The present studies suggest that WS070117 may be
used as a newer pharmacological agent to treat or con-
trol HFD-induced lipid metabolism disorder. Our results
also support the view that the anti-hyperlipidemia and
anti-steatosis effects of WS070117 may be attributed to
the activation of AMPK and inhibition of de novo hepa-
tic lipogenesis.
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